Scientists Crack the Code on How Alzheimer's Drug Lecanemab Actually Works

Researchers have finally cracked the code on how lecanemab, the FDA-approved Alzheimer's drug marketed as Leqembi, actually works in the brain. This breakthrough matters because while the drug shows promise in slowing cognitive decline, its side effects have limited benefits, and until now, scientists didn't understand its exact mechanism of action.

The key discovery centers on a specific part of the antibody called the Fc fragment, which acts like a molecular switch. When lecanemab encounters amyloid plaques in the brain, this fragment activates microglia, the brain's immune cells, prompting them to efficiently clear these toxic protein deposits that drive Alzheimer's progression.

Using an innovative mouse model containing human microglial cells, researchers from VIB and KU Leuven proved that the Fc fragment is absolutely essential. When they removed this component, the antibody became completely ineffective at clearing plaques. This human-specific testing approach provided unprecedented insight into how the drug works in actual patients.

The implications are significant for future Alzheimer's treatments. Understanding this mechanism could lead to safer, more effective therapies with fewer side effects. Currently, more than 55 million people worldwide live with Alzheimer's, and while microglia naturally gather around amyloid plaques, they typically can't remove them effectively without therapeutic intervention.

However, important caveats remain. This research was conducted in mouse models, and while human microglia were used, real-world effectiveness may vary. Additionally, lecanemab's side effects still pose challenges, and this mechanistic understanding doesn't immediately solve those safety concerns. The findings, published in Nature Neuroscience, represent a crucial step forward but don't guarantee immediate improvements in patient outcomes.